183 related articles for article (PubMed ID: 32856462)
1. Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin II Receptor Blockers: A Comparison of Outcomes in Patients With COVID-19.
Kalra A; Hawkins ES; Nowacki AS; Jain V; Milinovich A; Saef J; Thomas G; Gebreselassie SK; Karnik SS; Jehi L; Young JB; Svensson LG; Chung MK; Mehta N
Circ Cardiovasc Qual Outcomes; 2020 Oct; 13(10):e007115. PubMed ID: 32856462
[No Abstract] [Full Text] [Related]
2. A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19.
Wang Z; Zhang D; Wang S; Jin Y; Huan J; Wu Y; Xia C; Li Z; Qi X; Zhang D; Han X; Zhu X; Qu Y; Wang Q
Med Sci Monit; 2020 Sep; 26():e926651. PubMed ID: 32969367
[TBL] [Abstract][Full Text] [Related]
3. Associations Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blocker Use, Gastrointestinal Symptoms, and Mortality Among Patients With COVID-19.
Tan ND; Qiu Y; Xing XB; Ghosh S; Chen MH; Mao R
Gastroenterology; 2020 Sep; 159(3):1170-1172.e1. PubMed ID: 32422208
[No Abstract] [Full Text] [Related]
4. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19).
Mehta N; Kalra A; Nowacki AS; Anjewierden S; Han Z; Bhat P; Carmona-Rubio AE; Jacob M; Procop GW; Harrington S; Milinovich A; Svensson LG; Jehi L; Young JB; Chung MK
JAMA Cardiol; 2020 Sep; 5(9):1020-1026. PubMed ID: 32936273
[TBL] [Abstract][Full Text] [Related]
5. Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis.
Guo X; Zhu Y; Hong Y
Hypertension; 2020 Aug; 76(2):e13-e14. PubMed ID: 32458694
[No Abstract] [Full Text] [Related]
6. Renin-angiotensin system antagonists are associated with lower mortality in hypertensive patients with COVID-19.
Megaly M; Glogoza M
Scott Med J; 2020 Nov; 65(4):123-126. PubMed ID: 32807019
[TBL] [Abstract][Full Text] [Related]
7. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.
Vaduganathan M; Vardeny O; Michel T; McMurray JJV; Pfeffer MA; Solomon SD
N Engl J Med; 2020 Apr; 382(17):1653-1659. PubMed ID: 32227760
[No Abstract] [Full Text] [Related]
8. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.
Yang G; Tan Z; Zhou L; Yang M; Peng L; Liu J; Cai J; Yang R; Han J; Huang Y; He S
Hypertension; 2020 Jul; 76(1):51-58. PubMed ID: 32348166
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?
Patel AB; Verma A
JAMA; 2020 May; 323(18):1769-1770. PubMed ID: 32208485
[No Abstract] [Full Text] [Related]
10. Related molecular mechanisms of COVID-19, hypertension, and diabetes.
Akkus E; Sahin M
Am J Physiol Endocrinol Metab; 2020 Jun; 318(6):E881. PubMed ID: 32479159
[No Abstract] [Full Text] [Related]
11. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China.
Li J; Wang X; Chen J; Zhang H; Deng A
JAMA Cardiol; 2020 Jul; 5(7):825-830. PubMed ID: 32324209
[TBL] [Abstract][Full Text] [Related]
12. A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019).
Talreja H; Tan J; Dawes M; Supershad S; Rabindranath K; Fisher J; Valappil S; van der Merwe V; Wong L; van der Merwe W; Paton J
N Z Med J; 2020 Apr; 133(1512):85-87. PubMed ID: 32242182
[TBL] [Abstract][Full Text] [Related]
13. The Renin-Angiotensin-Aldosterone System in Coronavirus Infection-Current Considerations During the Pandemic.
Augoustides JGT
J Cardiothorac Vasc Anesth; 2020 Jul; 34(7):1717-1719. PubMed ID: 32360010
[No Abstract] [Full Text] [Related]
14. Potential differential effects of renin-angiotensin system inhibitors on SARS-CoV-2 infection and lung injury in COVID-19.
Furuhashi M; Moniwa N; Takizawa H; Ura N; Shimamoto K
Hypertens Res; 2020 Aug; 43(8):837-840. PubMed ID: 32433641
[No Abstract] [Full Text] [Related]
15. Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?
Huang Y; Xie C; Chen X; Hong Q; Huang H
Pharmacol Res; 2020 Sep; 159():104959. PubMed ID: 32505834
[No Abstract] [Full Text] [Related]
16. COVID-19 and Cardiovascular Disease.
Clerkin KJ; Fried JA; Raikhelkar J; Sayer G; Griffin JM; Masoumi A; Jain SS; Burkhoff D; Kumaraiah D; Rabbani L; Schwartz A; Uriel N
Circulation; 2020 May; 141(20):1648-1655. PubMed ID: 32200663
[TBL] [Abstract][Full Text] [Related]
17. Coronavirus disease 2019 (COVID-19): angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and cardiovascular disease.
Jennings GL
Med J Aust; 2020 Jun; 212(11):502-503.e1. PubMed ID: 32441063
[No Abstract] [Full Text] [Related]
18. Baseline use of angiotensin-converting enzyme inhibitor/AT1 blocker and outcomes in hospitalized coronavirus disease 2019 African-American patients.
Shah P; Owens J; Franklin J; Jani Y; Kumar A; Doshi R
J Hypertens; 2020 Dec; 38(12):2537-2541. PubMed ID: 32740406
[TBL] [Abstract][Full Text] [Related]
19. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis.
Xu J; Huang C; Fan G; Liu Z; Shang L; Zhou F; Wang Y; Yu J; Yang L; Xie K; Huang Z; Huang L; Gu X; Li H; Zhang Y; Wang Y; Hayden FG; Horby PW; Cao B; Wang C
Front Med; 2020 Oct; 14(5):601-612. PubMed ID: 32621202
[TBL] [Abstract][Full Text] [Related]
20. COVID-19 and the cardiovascular system.
Zheng YY; Ma YT; Zhang JY; Xie X
Nat Rev Cardiol; 2020 May; 17(5):259-260. PubMed ID: 32139904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
